Three deadly diseases: one approach

Wednesday, 24 February 2010

We are working with AMREF to develop a model for the integrated management of TB, HIV/AIDS and malaria in hard hit Uganda.

TB is the leading cause of death in people living with HIV. Together, the two diseases are a deadly combination. In Uganda, there is the added burden of malaria, which in that country causes more illness and death than any other single disease. There is compelling evidence that HIV infection results in greater risk of death from malaria because malaria infection increases the HIV viral load among adults, leading to increased mother-to-child transmission of HIV during pregnancy. The links between the three diseases are not being managed in an integrated way. For example, Ugandans with TB/HIV, malaria and other conditions have to attend separate health services for treatment.

Our partnership with the African Medical and Research Foundation (AMREF) is focused on developing a model for the integrated management of TB, HIV/AIDS and malaria at both national and local levels in Uganda.

This integrated management approach has not been widely addressed before and we are one of the few organisations involved in such work. A pilot programme is now underway in the high incidence areas of Luwero and Kiboga districts of central Uganda.

The main objectives of this work include increasing laboratory diagnostic capacity and improving community-based healthcare management.

Progress so far includes the completion, and handover to local district management teams of three new laboratories and the establishment of 144 village health teams, with a total of over 750 people trained in health promotion in their local communities.

AMREF is one of the partnerships that we have in place to help NGOs and other organisations in their work to combat TB and other diseases on the ground in vulnerable communities.

You can read more about this partnership, and our others, in the In the Developing World section.

How collaborative working can achieve the right safety profile

AZ scientists Mark Anderton and Ray Finlay discuss their role in re-designing an oncology compound

Achieving the right balance of benefit-risk is crucial; our job is to identify, characterise and eliminate molecules with negative benefit-risk balance as early and as quickly as possible.

Read the latest post on LabTalk


Read the latest blogs from our scientists working in our oncology portfolio

Oncology_compound_shows_THM 30 May 2014

Oncology compound shows how collaborative working can achieve the right safety profile

Driving open innovation across Asia THM 22 May 2014

AstraZeneca is driving open innovation across Asia